Literature DB >> 35402956

Predicting Lymphoma Development by Exploiting Genetic Variants and Clinical Findings in a Machine Learning-Based Methodology With Ensemble Classifiers in a Cohort of Sjögren's Syndrome Patients.

Konstantina D Kourou1,2, Vasileios C Pezoulas1, Eleni I Georga1, Themis Exarchos1,3, Costas Papaloukas1,2, Michalis Voulgarelis4, Andreas Goules4, Andrianos Nezos5, Athanasios G Tzioufas4, Earalampos M Moutsopoulos6, Clio Mavragani7,5, Dimitrios I Fotiadis1,4,6.   

Abstract

Lymphoma development constitutes one of the most serious clinico-pathological manifestations of patients with Sjögren's Syndrome (SS). Over the last decades the risk for lymphomagenesis in SS patients has been studied aiming to identify novel biomarkers and risk factors predicting lymphoma development in this patient population. Objective: The current study aims to explore whether genetic susceptibility profiles of SS patients along with known clinical, serological and histological risk factors enhance the accuracy of predicting lymphoma development in this patient population.
Methods: The potential predicting role of both genetic variants, clinical and laboratory risk factors were investigated through a Machine Learning-based (ML) framework which encapsulates ensemble classifiers.
Results: Ensemble methods empower the classification accuracy with approaches which are sensitive to minor perturbations in the training phase. The evaluation of the proposed methodology based on a 10-fold stratified cross validation procedure yielded considerable results in terms of balanced accuracy (GB: 0.7780 ± 0.1514, RF Gini: 0.7626 ± 0.1787, RF Entropy: 0.7590 ± 0.1837). Conclusions: The initial clinical, serological, histological and genetic findings at an early diagnosis have been exploited in an attempt to establish predictive tools in clinical practice and further enhance our understanding towards lymphoma development in SS.

Entities:  

Keywords:  Ensemble methods; Sjögren's Syndrome; genetic variants; lymphoma prediction; machine learning

Year:  2020        PMID: 35402956      PMCID: PMC8979630          DOI: 10.1109/OJEMB.2020.2965191

Source DB:  PubMed          Journal:  IEEE Open J Eng Med Biol        ISSN: 2644-1276


  28 in total

1.  BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands.

Authors:  Luca Quartuccio; Sara Salvin; Martina Fabris; Marta Maset; Elena Pontarini; Miriam Isola; Salvatore De Vita
Journal:  Rheumatology (Oxford)       Date:  2012-08-09       Impact factor: 7.580

2.  Medical data quality assessment: On the development of an automated framework for medical data curation.

Authors:  Vasileios C Pezoulas; Konstantina D Kourou; Fanis Kalatzis; Themis P Exarchos; Aliki Venetsanopoulou; Evi Zampeli; Saviana Gandolfo; Fotini Skopouli; Salvatore De Vita; Athanasios G Tzioufas; Dimitrios I Fotiadis
Journal:  Comput Biol Med       Date:  2019-03-07       Impact factor: 4.589

3.  Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome.

Authors:  Gaetane Nocturne; Saida Boudaoud; Corinne Miceli-Richard; Say Viengchareun; Thierry Lazure; Joanne Nititham; Kimberly E Taylor; Averil Ma; Florence Busato; Judith Melki; Christopher J Lessard; Kathy L Sivils; Jean-Jacques Dubost; Eric Hachulla; Jacques Eric Gottenberg; Marc Lombès; Jorg Tost; Lindsey A Criswell; Xavier Mariette
Journal:  Blood       Date:  2013-10-24       Impact factor: 22.113

4.  Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome.

Authors:  John P A Ioannidis; Vassilios A Vassiliou; Haralampos M Moutsopoulos
Journal:  Arthritis Rheum       Date:  2002-03

5.  The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren's syndrome.

Authors:  Anna P Risselada; Aike A Kruize; Roel Goldschmeding; Floris P J G Lafeber; Johannes W J Bijlsma; Joel A G van Roon
Journal:  Ann Rheum Dis       Date:  2014-02-13       Impact factor: 19.103

6.  Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients.

Authors:  Aristea Papageorgiou; Dimitrios C Ziogas; Clio P Mavragani; Elias Zintzaras; Athanasios G Tzioufas; Haralampos M Moutsopoulos; Michael Voulgarelis
Journal:  PLoS One       Date:  2015-02-27       Impact factor: 3.240

7.  MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome.

Authors:  Sofia Fragkioudaki; Adrianos Nezos; Vassilis L Souliotis; Ilenia Chatziandreou; Angelica A Saetta; Nikolaos Drakoulis; Athanasios G Tzioufas; Michael Voulgarelis; Petros P Sfikakis; Michael Koutsilieris; Mary K Crow; Haralampos M Moutsopoulos; Clio P Mavragani
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

8.  Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use.

Authors:  Sofia Fragkioudaki; Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

9.  TNFAIP3 F127C Coding Variation in Greek Primary Sjogren's Syndrome Patients.

Authors:  Adrianos Nezos; Eliona Gkioka; Michael Koutsilieris; Michael Voulgarelis; Athanasios G Tzioufas; Clio P Mavragani
Journal:  J Immunol Res       Date:  2018-12-19       Impact factor: 4.818

10.  Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma.

Authors:  Gaetane Nocturne; Jessica Tarn; Saida Boudaoud; James Locke; Corinne Miceli-Richard; Eric Hachulla; Jean-Jacques Dubost; Simon Bowman; Jacques-Eric Gottenberg; Lindsey A Criswell; Christopher J Lessard; Kathy L Sivils; Raphael Carapito; Siamak Bahram; Raphaèle Seror; Wan-Fai Ng; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2015-09-02       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.